
A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.
Learn about the typical state-of-the-art setup for high-throughput peptide mapping using chromatography and mass spectrometry (MS) techniques, as well as ways of simplifying mapping data.






